Why Oral Formulation Raises Probability Of Success

An oral Lucid MS should lift adherence and reduce discontinuations in Phase 2, especially versus injectable regimens. Better adherence means cleaner exposure response and fewer protocol deviations, which makes PET MRI endpoints more reliable. The CDMO agreement ensures consistent quality and timely supply, which reduces startup friction at sites. Combine that with Phase 1 safety already confirmed and IND paperwork moving, and trial risk shifts from logistics to pure biology. For traders, levels remain straightforward. 25.40 is your fail safe, 26.00 the go line, 28.00 the momentum gate. If interim imaging validates the mechanism, rerating pressure grows quickly in a small float.